Please login to the form below

Not currently logged in
Email:
Password:

everolimus

This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been

Latest news

  • AAA board presses go on $3.9bn Novartis takeover AAA board presses go on $3.9bn Novartis takeover

    Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective,

  • NICE U-turn on Novartis' Afinitor for kidney cancer NICE U-turn on Novartis' Afinitor for kidney cancer

    cancer. The U-turn on NICE's 2011 decision comes as the regulator continues its reappraisal of all therapies supported by the Cancer Drugs Fund (CDF), with Afinitor (everolimus) previously only

  • NICE backs Novartis' Afinitor and Pfizer's Xalkori NICE backs Novartis' Afinitor and Pfizer's Xalkori

    Afinitor (everolimus) has been backed as a combination treatment with Pfizer's Aromasin (exemestane) for the treatment of postmenopausal women with HER2-negative hormone-receptor-positive advanced breast cancer - the most ... organs. Prof Carole Longson,

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    In a phase III clinical study, patients treated with Opdivo lived for an average of 5.4 months longer than the group who received Novartis' Afinitor (everolimus), the standard therapy, and

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Since then NICE's deliberations over how to apply the new rules have caused considerable uncertainty for Novartis' breast cancer therapy Afinitor (everolimus) and Janssen's Imbruvica (ibrutinib) for mantle cell

More from news
Approximately 10 fully matching, plus 74 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

  • Oncology drugs under AMNOG

    patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics